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RT-qPCRHantavirus cardiopulmonary syndrome is a severe disease caused by exposure to New World hantaviruses.
Early diagnosis is difﬁcult due to the lack of speciﬁc initial symptoms. Antihantavirus antibodies are usually
negative until late in the febrile prodrome or the beginning of cardiopulmonary phase, while Andes hantavirus
(ANDV) RNA genome can be detected before symptoms onset. We analyzed the effectiveness of quantitative re-
verse transcription polymerase chain reaction (RT-qPCR) as a diagnostic tool detecting ANDV-Sout genome in
peripheral blood cells from 78 conﬁrmed hantavirus patients and 166 negative controls. Our results indicate
that RT-qPCR had a lowdetection limit (~10 copies), with a speciﬁcity of 100% and a sensitivity of 94.9%. This sug-
gests the potential for establishing RT-qPCR as the assay of choice for early diagnosis, promoting early effective
care of patients, and improving other important aspects of ANDV infection management, such as compliance of
biosafety recommendations for health personnel in order to avoid nosocomial transmission.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Hantaviruses are enveloped, segmented, negative strand-RNA virus-
es that belong to the Bunyaviridae family. The genome is composed by 3
segments: S, which encodes for the nucleocapsid (N) protein; M, which
encodes for the membrane glycoproteins Gn and Gc; and L, which en-
codes for the RNA-dependent RNA polymerase (Meissner et al., 2002;
Plyusnin et al., 1996). There are 2 main categories for hantavirus dis-
eases, depending on organs involved and source of infection: hemor-
rhagic fever with renal syndrome, mainly in Asia and Europe, are
caused by Old World hantaviruses, while hantavirus cardiopulmonary
syndrome (HCPS), in North and South America, are caused by New
World hantaviruses (Hjelle and Torres-Pérez, 2010; Manigold and
Vial, 2014; Pini, 2004). Speciﬁcally, in South America, there are 4 differ-
ent phylogenetic clades of hantaviruses corresponding to Andes, Laguna
Negra, Rio Mamore, and Jabora hantaviruses (Firth et al., 2012; Souza
and Figueiredo, 2014). Several South American hantaviruses have
been associated to HCPS cases, including Andes, Anajatuba, Araraquara
(ARQV), Paranoá, Bermejo, Castelo dos Sonhos, Juquitiba, Araucária,
Laguna Negra, Lechiguanas, Maripa, Oran, Rio Mamore, and Tunari; A
total of approximately 4000 cases associated to these hantavirus have
been reported in South America (Figueiredo et al., 2014; Manigold and
Vial, 2014).56-223-279-639.
. This is an open access article underAndes hantavirus (ANDV) is endemic in Chile and Argentina. Specif-
ically, ANDV-Sout strain is the variant circulating in Chile and South of
Argentina. This is the only hantavirus known to be transmissible be-
tween humans (Martinez et al., 2005; Padula et al., 1998). According
to reports from the Chilean Department of Health, through December
31, 2014, a total of 902 cases have been reported in Chile with a case fa-
tality rate between 30% and 40% depending on the clinical center per
year (Unidad de Vigilancia/Departamento de Epidemiologia/MINSAL,
2012, 2014, 2015). The main reservoir for ANDV is the long-tailed
pygmy rice rat (Oligoryzomys longicaudatus) (Palma et al., 2012), and
transmission to humans occurs primarily by inhalation of the virus in
aerosolized rodent excretions (Lee and van der Groen, 1989; Wells
et al., 1997). This mechanism suggests that people living in rural areas
or routinely performing activities in these locations such as farmers, forest
workers, or people who engage in recreational activities in endemic
places havemore chance of becoming infected. In cases of ANDV infection,
sexual partners and contacts who slept in the same bed during the
prodromic period of the case have 10 timesmore risk of becoming infect-
ed when compared to other household contacts (Ferres et al., 2007). The
incubation period of ANDV varies from7 to 39 days (Vial et al., 2006), and
viral particles can be detected in blood as early as 2 weeks prior to symp-
toms or antibody response (Evander et al., 2007; Ferres et al., 2007).
There are 4 distinguishable stages in the clinical course of HCPS:
Prodromic stage, which lasts between 2 and 8 days and that presents
with unspeciﬁc symptoms that include but are not limited to, fever, my-
algia, headache, and gastrointestinal symptoms. Patients frequentlythe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
37C. Vial et al. / Diagnostic Microbiology and Infectious Disease 84 (2016) 36–39seek attention during this stage but diagnosis is rarely made and serol-
ogy, if requested, is usually negative. The cardiopulmonary stage, which
presentswith development of dry cough, but can rapidly (within hours)
set patients on the course for severe respiratory distress and shock,
leading to death in one-third of the cases. The diuretic stage, character-
ized by full normalization of lung and cardiac functions in patients
who survive the cardiopulmonary stage. These patients are usually
dischargedwithout evident sequelae in 1 or 2weeks. Finally, the conva-
lescent stage, in which some patients can still present with fatigue and
malaise for weeks to months before fully recovering (Castillo, 2001;
Duchin et al., 1994; Ferrés and Vial, 2004; Hallin et al., 1996; Riquelme
et al., 2003; Sotomayor et al., 2009).
At present, reference centers in Chile and Argentina diagnose ANDV
hantavirus infection through enzyme-linked immunosorbent assay
(ELISA) for detection of IgM antibodies against hantavirus N protein
(Padula et al., 2000). While these results are of high quality, frequently
they are not available in the early stages of disease, where critical pa-
tient management decisions are required, leaving this process relying
solely on clinical and epidemiological parameters. Other hematological
parameters, such as thrombocytopenia, elevated white cell count, im-
mature granulocytes, and distinctive immunoblast cells are also sup-
portive of a diagnosis of HCPS (Sotomayor et al., 2009). In many
hospitals in Chile a commercially available, rapid test for IgM against
Puumala hantavirus (Reagena POC® Puumala IgM) is also available,
but its performance is not optimal. None of these techniques allow for
an early diagnosis, as IgM may become detectable only during late
stages of prodromic phase or at the beginning of the cardiopulmonary
phase. HCPS patients have high levels of viremia (Terajima et al.,
1999; Xiao et al., 2006), andwe have previously found that quantitative
reverse transcription polymerase chain reaction (RT-qPCR) can detect
the presence of ANDV in blood early in the disease, identifying viral
RNA even before symptoms appear (Ferres et al., 2007). Despite this
promising performance, RT-qPCR is still considered a research tool. In
this study, we evaluate the performance of RT-qPCR as a diagnostic
tool for ANDV infections and show that it complies with every require-
ment to become the assay of choice for early diagnosis of ANDV
infections.
2. Materials and methods
2.1. Samples
Weanalyzed blood samples from 244 anonymized patients whohad
been previously enrolled in different protocols fromourHantavirus Pro-
gram between years 2001 and 2013: household contacts follow-up
(Ferres et al., 2007); 2 treatment protocols: methylprednisolone (Vial
et al., 2013) and immune plasma protocol (Vial et al., 2015); and a ge-
netic study (a genome wide association study) (Fondecyt 1110397).
Stored white blood cell (WBC) samples were obtained from whole
blood drawn at the time of enrollment in the pertinent study, between
days 0 and 3 of hospitalization. Peripheral blood was obtained by
venipuncture, collected in EDTA blood tubes (4 mL), and separated by
centrifugation at low speed (1000 rpm for 15 minutes). After centrifu-
gation, buffy coat containing WBC was removed with a small volume
of plasma (200 μL) and stored at−80 °C until further use. Hantavirus-
positive patients were diagnosed on the basis of the presence of either
a febrile prodrome followed by a cardiopulmonary phase with the de-
velopment of bilateral pulmonary changes (determined by chest radi-
ography) that may or may not trigger cardiogenic shock or by
detection of antihantavirus antibodies by ELISA as discussed before.
We also included samples from 166 negative household contacts of
HCPS cases that were obtained between 1 and 5 weeks after HCPS
index case detection. These contacts were followed during 40 days, pe-
riod during which they did not develop any symptoms and remained
serologically negative to hantavirus. All participants signed an informed
consent, previously approved by institutional ethics committees.2.2. Enzyme-linked immunosorbent assay (serology)
ANDV-reactive antibodies were detected through an IgM capture
ELISA performed with patient sera and recombinant ANDV N protein
following previously described procedures (Padula et al., 2000).
2.3. Viral RNA extraction and RT-qPCR
We extracted Viral RNA from peripheral WBC of patients from a
starting volume of 200 μL using High Pure Viral RNA Kit (Roche Diagnos-
tics, Indianapolis, IN) according to manufacturer instructions, obtaining
approximately 50 μL of RNA. For the reverse transcription reaction, 5 μL
of extracted RNA was used for cDNA synthesis (between 250 and
400 ng/μL RNA) with MMLV enzyme (Invitrogen, Carlsbad, CA) and
ANDV-speciﬁc primer (forward strand) in a ﬁnal reaction volume of 20 μL.
Real-time PCR was performed following a previously described
method (Kramski et al., 2007), as detailed in Supplementary Tables 1
and 2. All PCRswere doneby anoperatorwhowasblinded to the clinical
diagnosis of the samples, in a Light Cycler 2.0 thermal cycler (Roche
Appl Biosc) except for the experiment comparing different thermal cy-
clers. PCRs were cataloged as positive when the crossing point (Cp)was
less than 36. The whole process from RNA isolation to the RT-qPCR re-
sult takes around 3 hours and 30 minutes.
2.4. Plasmid preparation
We extracted RNA from in vitro cultured ANDV (Galeno et al., 2002),
and RT-qPCR was performed using primers from S segment described
in Supplementary Table 1 (Kramski et al., 2007). For the ligation step,
we added adenine to the ampliﬁed product using Platinum®Taq DNA
polymerase (Life Technologies, Carlsbad, CA). Brieﬂy, 1 U of polymerase
and 10 nmol/L of dATP (Fermentas, Waltham,MA)were added to 10 μg
of PCR product and incubated for 20 min at 72 °C. We separated the
product in a 1% agarose gel stained with SYBR® Safe DNA gel stain
(Life Technologies), and the product was extracted from the gel using
Wizard® SV gel (Promega Corporation, Madison, WI) and PCR Clean-
Up System (Promega Corporation). Plasmid pGemT-easy (Promega Cor-
poration) and PCR fragments were ligated according to manufacturer
instructions. Escherichia coli (DH5α) competent bacteria were trans-
formed with the plasmid, grown in LB medium (Life Technologies), and
selected by Ampicillin (Life Technologies). The plasmid was puriﬁed,
quantiﬁed, and stored.
2.5. In vitro transcribed RNA
S segment RNAwas kindly donated byMarcelo Lopez-Lastra and pro-
duced by in vitro transcription using T7 RNA polymerase (Fermentas) as
described (Vera-Otarola et al., 2012).
2.6. Statistical analysis
Concordance between diagnostic methods (RT-qPCR versus ELISA)
was evaluated through calculation of the kappa coefﬁcient (κ) using
SPSS v20 (IBM, Armonk, NY). Diagnostic test parameterswere calculated
with Epidat v3.1 (Panamerican Health Association OPS).
3. Results
3.1. Analytical detection limit
Weperformed RT-qPCRs for ANDV on serial dilutions of known copy
number of either an in vitro transcribed RNA or a plasmid containing
cDNA of the S segment. In Fig. 1, we show the corresponding Cp value
for the logarithm of each dilution and compared these results between














Fig. 2.Comparisonof real-timeANDVassays performed in2 platforms. Real-time PCRplat-
forms LightCycler 480® (LC480) and LightCycler 2.0 (LC2.0) were used to assay the same
amount of RNA copies. The graphic shows the comparison of the crossing point (Cp) for
different amounts of in vitro transcribed RNA and 2 technical duplicates for each
LightCycler platform.
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groups all the data points, showing that the 2-step assay has a better
efﬁciency (91.8%) than the 1-step assay (82.7%) (Supplementary
Table 3). We also performed the 2-step assay on a plasmid containing
the S segment, and this reaction had an efﬁciency of 97%. Since the
efﬁciencywas better in the 2-step reaction, we performed all the exper-
imentswith patient samples using thismethod. Using this experimental
data, we calculated that the 2-step method has a limit of detection
(LOD) of 11.96 RNA copies/reaction (95% conﬁdence interval [CI]:
0–11.96, logistic regression). The linear range of the RT-qPCR was
between 107 and 10 copies/reaction.
3.2. Technical reproducibility in 2 real-time platforms
We run parallel serial dilutions of in vitro transcribed RNA to com-
pare the assay performance in 2 different Light Cycler models
(LighCycler 480® and LightCyler 2.0). As shown in Fig. 2, both platforms
behaved similarly, indicating that the method can be extrapolated to
other qPCR machines.
3.3. Patient sample analysis
We analyzed 244 human samples, 78 from positive hantavirus pa-
tients and 166 from controls, categorized as described in Materials
and methods. In Table 1, we show the 2-step RT-qPCR results in which
we found 240/244 concordant samples. Concordance between hantavi-
rus cases and RT-qPCR had a kappa value of 0.96. To evaluate the perfor-
mance of RT-qPCR as a diagnostic tool, we compared it to hantavirus-
positive and hantavirus-negative patients as a gold standard (Table 2)
and found that RT-qPCR is very sensitive and highly speciﬁc, yielding
high predictive positive and negative values, which converts this tech-
nique into an outstanding diagnostic test.
4. Discussion
We have validated the use of RT-qPCR in WBCs as a robust tool for
the diagnosis of ANDV-Sout infection, displaying high sensitivity, speci-
ﬁcity, and positive and negative predictive values. Others have previ-
ously detected hantavirus by RT-qPCR, but to our knowledge, this is
the ﬁrst effort to validate this technique as a diagnostic tool in a large
number of patients (Evander et al., 2007; Ibrahim et al., 2011; Machado
and Souza, 2013).
Perhaps the characteristic of infection by ANDV that mostly in-
creases mortality is that initial symptoms of hantavirus infections are
highly unspeciﬁc and difﬁcult to differentiate from other febrile ill-
nesses. Because patients with hantavirus infection require urgent refer-
ral to a center with complex intensive care facilities, availability of the
RT-qPCR assay is of tremendous relevance, since it has been proven as
a reliable diagnostic test at early stages and could be used to direct they = -3.8197x + 33.181
R² = 0.9561
y = -3.535x + 39.624
R² = 0.9883


























Fig. 1. RT-qPCR for ANDV. Known amounts of in vitro transcribed S segment RNAwas am-
pliﬁed by 1-step reaction (circles) or 2-step reaction (crosses). A plasmid (P) containing S
Segment sequence (triangles) was assayed in a 2-step RT-qPCR reaction. All experiments
were done in LightCycler 2.0.decision-making process more efﬁciently. Also, an accurate and faster
diagnosis is important in the reinforcement and adherence to isolation
precautions in the health personnel to avoid nosocomial transmission
(Martinez-Valdebenito et al., 2014). This method contrasts to
hantavirus-speciﬁc antibodies detection, which is usually not reliable
until late into the febrile prodromeor beginning of the cardiopulmonary
stage,making serologic testingnot useful for early diagnosis. Ferres et al.
(2007) reported that they can detect viral RNA in peripheral blood
cells 5–15 days prior to the onset of symptoms and before the appear-
ance of antihantavirus antibodies, so RT-qPCR could prove a better
tool than classic antibody detection by ELISA for diagnosis in an early
phase of illness. This is also true for a few cases where even in the car-
diopulmonary stage, serology by ELISA was negative, probably due to
a slow immunological response of the patient (Martinez-Valdebenito
et al., 2014). In addition, ANDV has been detected by RT-qPCR even
84 days after ﬁrst day of hospitalization (Ferres et al., 2007; Vial et al.,
2013), making PCR a good diagnostic tool at different stages of the dis-
ease, contrasting with infections such as dengue that have shorter vire-
mia (Tang and Ooi, 2012).
Because WBC is the compartment with the highest viral load when
compared to respiratory secretions, saliva, urine, and gingival crevicular
ﬂuid (Ferres et al., 2007; Godoy et al., 2009), it is probably the best sam-
ple for diagnosis. Despite the general good performance of RT-qPCR in
WBC as a diagnostic tool, it failed to detect the viral RNA in 4 of the
study samples (4 of 78, or 5%).We attribute thisﬁnding to the long stor-
age time of these samples (3–10 years, at−80 °C) causing viral RNA
degradation, a hypothesis supported by the observation of a sensitivity
of 100%when RT-qPCRwas done in fresh samples (data not shown). Al-
though we have not had false-negative results when analyzing fresh
samples, the negative result in the RT-qPCR test should not be conﬁrma-
tory. Overall, because HCPS has a high lethality, we think that the nega-
tive diagnosis should always be conﬁrmedby serology, and if symptoms
supportive of clinical diagnosis are maintained, a second PCR a day later
should be performed.
The RT-qPCR tool has very low technical LOD and high technical re-
producibility; thus, it can be used in diverse platforms, having a high
technical sensitivity and speciﬁcity for detecting ANDV. Although the
1-step assay is widely used in virology for diagnosis, we found that,
for this particular RT-qPCR, the 2-step assay had better efﬁciency, so
this should be the test of choice for early ANDV detection and decisionTable 1
RT-qPCR results in hantavirus patients.
Hantavirus positive Hantavirus negative Total
PCR positive 74 0 74
PCR negative 4 166 170
Total 78 166 244a
a Measure of agreement kappa for the 244 samples = 0.962.
Table 2
Clinical diagnostic parameters of RT-qPCR.
Value CI (95%)
Sensitivity (%) 94.9 89.3–100
Speciﬁcity (%) 100 99.7–100
Positive predictive value (%) 100 99.3–100
Negative predictive value (%) 97.7 95.1–100
Likelihood ratio (+)
Likelihood ratio (−) 0.05 0.02–0.13
39C. Vial et al. / Diagnostic Microbiology and Infectious Disease 84 (2016) 36–39making, although conﬁrmation of diagnosis by the national reference
laboratories is still required.
In order to prove the reproducibility of this technique, we compared
RT-qPCR results done in 2 different diagnosis centers, by 4 different
technicians, ﬁnding that Cp results are similar (data not shown), show-
ing this technique is highly reproducible. This should allow hospitals
across the country equipped to perform RT-qPCR the performance of
this test that should be done in adherence to good laboratory quality
control practices. This will allow the use of this technique on site
allowing a fast delivery of results and improving the standard of care
for patients with ANDV.
4.1. Conclusions
In this study, we have validated the use of 2-step RT-qPCR as a diag-
nostic tool for ANDV-Sout. RT-qPCR can become an excellent tool for di-
agnosis allowing early and fast viral detection, positively affecting
patient management.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.diagmicrobio.2015.07.019.
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